We will evaluate the efficacy and safety of combination therapy of 10 mg mitiglinide or 0.2mg voglibose with insulin glargine for 16 weeks after single administration of insulin glargine for 4 weeks in type 2 diabetic patients whose glycemic control were not enough despite administration of oral antidiabetic drug or insulin glargine.

Inclusion Criteria:

• The type 2 diabetic patients aged between 30 and 70
• The patients whose Hb1Ac is over 7.0% despite administration of two or more oral antidiabetic drugs over 6 months or only insulin glargine over 3 months before registration
• Outpatients whose BMI is between 21 and 40 kg/㎡
• The patients who consented to participate in the clinical study in writing

Exclusion Criteria:

• The patients who have been using insulin formulation except insulin glargine
• The patients whose fasting blood glucose is over 270 mg/dL
• The patients whose C-peptide is under 1ng/ml on an empty stomach
• The patients who was surgically operated of gastrointestinal tract
• The patients who need additional treatment or who underwent operation within 3 months for severe complication such as diabetic foot ulcer, retinopathy and neuropathy
• The patients with severe hepatic dysfunction : uncompensated hepatic cirrhosis, or the case where aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is over 2.5 times higher than the normal limit ( ≥ 2.5 x normal ranges)
• The patients with unstable angina or acute myocardial infarction occurred within 3months
• The patients with renal failure or severe hypertension : diastolic blood pressure is over 110mmHg despite drug treatment
• The patients who have a life-threatening disease such as cancer or severe infection
• The patients with a history of drug allergy
• Pregnant or breast feeding or the women who are likely to be pregnant
• The patients who need oral or parenteral corticosteroids
• The patients who were judged to be unsuitable to the clinical study by other reasons